Back to results
US 9,067,915 B2Granted
Sunitinib and salts thereof and their polymorphs
AssigneeTeva Pharmaceutical Industries Ltd.
InventorsAlexandr Jegorov, Ales Gavenda, Pavel Vraspir, Augusto Canavesi, Francesca Scarpitta
Life of this patent
Estimating the term…
Abstract
Process for the preparation of sunitinib malate form I via sunitinib acetate and polymorphs of said intermediate.
Claims5
A crystalline form of Sunitinib acetate characterized by data selected from the group consisting of:
- a PXRD pattern having peaks at about 6.1, 11.0, 15.8, 16.4 and 20.2±0.2 degrees 2-theta,
- a PXRD pattern as depicted in FIG. 17,
- a solid-state 13C NMR spectrum having signals at about 166.1, 133.0, 119.0, 114.5, 109.9 and 108.6±0.2 ppm,
- a solid-state 13C NMR spectrum having chemical shifts differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 100 to 180 ppm of about 65.0, 31.9, 17.9, 13.4, 8.8 and 7.5±0.1 ppm,
- a solid-state 13C NMR spectrum depicted in FIG. 21;
- and combinations thereof.
3 more elements
Dependencies are inferred from the claim text.